標(biāo)題: Titlebook: Antithrombotics; Andrew C. G. Uprichard (Vice President),Kim P. Gal Book 1999 Springer-Verlag Berlin Heidelberg 1999 Antithrombin.Arzneimi [打印本頁] 作者: affected 時(shí)間: 2025-3-21 19:19
書目名稱Antithrombotics影響因子(影響力)
書目名稱Antithrombotics影響因子(影響力)學(xué)科排名
書目名稱Antithrombotics網(wǎng)絡(luò)公開度
書目名稱Antithrombotics網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Antithrombotics被引頻次
書目名稱Antithrombotics被引頻次學(xué)科排名
書目名稱Antithrombotics年度引用
書目名稱Antithrombotics年度引用學(xué)科排名
書目名稱Antithrombotics讀者反饋
書目名稱Antithrombotics讀者反饋學(xué)科排名
作者: ANNUL 時(shí)間: 2025-3-21 20:21 作者: PRISE 時(shí)間: 2025-3-22 02:38
Alexandr. A. Ovchinnikov,Ivan I. UkrainskiiIn this chapter, we present a summary of the blood coagulation process and the status of current antithrombotic strategies. Due to space limitations, pertinent reviews are cited whenever possible from which the reader can obtain additional primary references.作者: 承認(rèn) 時(shí)間: 2025-3-22 05:02
The Coagulation Pathway and Antithrombotic Strategies,In this chapter, we present a summary of the blood coagulation process and the status of current antithrombotic strategies. Due to space limitations, pertinent reviews are cited whenever possible from which the reader can obtain additional primary references.作者: 自負(fù)的人 時(shí)間: 2025-3-22 09:46 作者: 代替 時(shí)間: 2025-3-22 15:00
978-3-642-64190-9Springer-Verlag Berlin Heidelberg 1999作者: 瑣事 時(shí)間: 2025-3-22 18:51
Wayne B. Nottingham,R H. Good,P. F. Littlemechanism involves the formation of hemostatic plugs by activation of platelets and polymerization of fibrin. Initiation of the plasma coagulation system upon exposure of blood to nonvascular cells is triggered by tissue factor (TF), which is expressed by a variety of cells surrounding the vasculatu作者: 整潔漂亮 時(shí)間: 2025-3-23 00:37 作者: laceration 時(shí)間: 2025-3-23 02:36
https://doi.org/10.1007/978-1-4613-2357-0ansient ischemic attack, or deep vein thrombosis (DVT). These thrombotic diseases are most common in the Western industrialized countries and affect millions of people every year (HIRSH and HOAK 1996). Over the last several decades, a variety of experimental models of thrombosis have been developed 作者: Foregery 時(shí)間: 2025-3-23 07:21
Isao Shimamura,Kazuo Takayanagito prevent spontaneous thrombosis. In evolutionary terms, a haemostatic system which is partially activated favours a successful response to injury. Agents such as warfarin and heparin which inhibit the procoagulant effect of the haemostatic system inevitably have anticoagulant effects which favour 作者: 勛章 時(shí)間: 2025-3-23 13:14 作者: alleviate 時(shí)間: 2025-3-23 14:57 作者: 預(yù)示 時(shí)間: 2025-3-23 21:29
https://doi.org/10.1007/978-1-4684-6988-2formation of a haemostatic plug and cessation of bleeding. The quiescent state of the platelet is maintained in part by the inhibitory action of constitutively released nitric oxide from endothelial cells lining the blood vessels. Activation is brought about by contact with extracellular matrix prot作者: 愚笨 時(shí)間: 2025-3-23 22:49
Unconventional Superconductivity,es and Western type of lifestyle proliferates. In the United States alone, over 150000 venous thromboses and 1.5 million myocardial infarctions occur per year. The majority of these patients require the administration of antithrombotic therapy. Heparin has the distinction of being the oldest antithr作者: 錯(cuò)誤 時(shí)間: 2025-3-24 05:15
https://doi.org/10.1007/978-3-642-14968-9edures. Furthermore, unfractionated heparin, given by a continuous intravenous infusion with laboratory monitoring using the activated partial thromboplastin time (APTT), with warfarin starting on day 1 or day 2 and continued for 3 months, has been the standard treatment of established venous thromb作者: 熱烈的歡迎 時(shí)間: 2025-3-24 09:31
Theory of Jahn-Teller Transitions,, cerebral vascular accidents, and limb and bowel ischemia. Thrombin plays a central role in the process of thrombosis. Heparin, which is currently the mainstay of antithrombotic therapy for the acute phase of all of these clinical syndromes, is only partially effective. The limitations of heparin t作者: Seizure 時(shí)間: 2025-3-24 14:44 作者: dainty 時(shí)間: 2025-3-24 16:29 作者: 移動(dòng) 時(shí)間: 2025-3-24 19:21 作者: alabaster 時(shí)間: 2025-3-25 01:50 作者: altruism 時(shí)間: 2025-3-25 05:59 作者: BILIO 時(shí)間: 2025-3-25 09:53
Book 1999c and anti-coagulant strategies as well as a summary of current research interest in the area and potential future targets. It attempts to balance traditional pharmacology with the newer sciences of molecular biology and in so doing, sets a framework for future advances in the field. The book is a c作者: dowagers-hump 時(shí)間: 2025-3-25 15:34 作者: 按等級(jí) 時(shí)間: 2025-3-25 18:50
Unconventional Superconductivity,ombotic and, along with a number of the agents, it is identified as an indirect antithrombotic agent (Table 1) because it inhibits thrombin via the potentiation of an endogenously occurring natural inhibitor.作者: Germinate 時(shí)間: 2025-3-25 22:04 作者: Unsaturated-Fat 時(shí)間: 2025-3-26 02:23 作者: 一再遛 時(shí)間: 2025-3-26 07:34
Heparin and Other Indirect Antithrombin Agents,ombotic and, along with a number of the agents, it is identified as an indirect antithrombotic agent (Table 1) because it inhibits thrombin via the potentiation of an endogenously occurring natural inhibitor.作者: Critical 時(shí)間: 2025-3-26 11:02 作者: ELATE 時(shí)間: 2025-3-26 15:09
Oral Thrombin Inhibitors: Challenges and Progress, development of oral thrombin inhibitors therefore presents a notable medical opportunity for improving the treatment of these cardiovascular disorders and currently represents a major challenge for pharmaceutical researchers.作者: 男學(xué)院 時(shí)間: 2025-3-26 19:33 作者: 螢火蟲 時(shí)間: 2025-3-26 23:13
0171-2004 -thrombotic and anti-coagulant strategies as well as a summary of current research interest in the area and potential future targets. It attempts to balance traditional pharmacology with the newer sciences of molecular biology and in so doing, sets a framework for future advances in the field. The b作者: Gratulate 時(shí)間: 2025-3-27 03:26 作者: 航海太平洋 時(shí)間: 2025-3-27 07:59 作者: 減至最低 時(shí)間: 2025-3-27 11:03 作者: 蹣跚 時(shí)間: 2025-3-27 13:57 作者: Cabg318 時(shí)間: 2025-3-27 19:50 作者: peak-flow 時(shí)間: 2025-3-28 00:34 作者: 煩人 時(shí)間: 2025-3-28 02:06 作者: PET-scan 時(shí)間: 2025-3-28 07:59 作者: stratum-corneum 時(shí)間: 2025-3-28 13:32 作者: brachial-plexus 時(shí)間: 2025-3-28 15:00 作者: 開頭 時(shí)間: 2025-3-28 18:57
Roundtable on Numerical Methods, Ilb/IIIa inhibitor). Given the novelty of abciximab, a substantial portion of this chapter will review the preclinical and clinical development of this monoclonal antibody as antiplatelet therapy for the treatment of ischemic complications associated with percutaneous coronary revascularization. A 作者: 富饒 時(shí)間: 2025-3-29 02:42 作者: FAWN 時(shí)間: 2025-3-29 05:30
https://doi.org/10.1007/978-3-642-14968-9n and treatment of venous thromboembolism. The low molecular weight heparins have also been used in clinical trials for the prevention and treatment of arterial thrombosis. In this chapter, we review the problems related to the use of unfractioned heparin, compare the low molecular weight heparins w作者: Emmenagogue 時(shí)間: 2025-3-29 09:38
Solitons and Charge Density Waves,o activate factors V, VIII and XI. Recruitment of these additional factors begins the “augmentation stage” which can provide large amounts of additional thrombin that plays a dominant role in subsequent thrombus formation. In both the classical coagulation cascade and the more current tissue factor 作者: Canyon 時(shí)間: 2025-3-29 13:41
Overview of Radiation from Dense Media, of additional thrombin and, thereby, fibrin. Although the TF/VIIa complex is not directly responsible for the production of all of the thrombin needed to form a complete thrombus, it plays the crucial role of initiating the process.作者: 含沙射影 時(shí)間: 2025-3-29 17:43
R. H. Avakian,K. A. Ispirian,V. J. Yaralov exposure of negatively charged phospholipids. These clotting reactions are offset by natural anticoagulant mechanisms, the most important of which are thought to include the tissue factor pathway inhibitor (Chap. 15), antithrombin-heparin (Chap. 9) and the protein C anticoagulant pathway (depicted 作者: ABIDE 時(shí)間: 2025-3-29 20:23 作者: 古老 時(shí)間: 2025-3-30 03:27 作者: geometrician 時(shí)間: 2025-3-30 08:06
Monitoring Antithrombotic Therapy,te the antithrombotic effects from the global anticoagulant effects of currently available agents, the therapeutic window of such agents tends to be narrow, and dose adjustment requires regular therapeutic monitoring.作者: 起來了 時(shí)間: 2025-3-30 09:11 作者: Incise 時(shí)間: 2025-3-30 15:05
Platelet Membrane Receptors and Signalling Pathways: New Therapeutic Targets,In the most severe cases, this leads to myocardial infarction or stroke, two of the major causes of death in the Western world. The platelet, therefore, is a major target for therapeutic intervention in the prevention of thrombotic disease.作者: Arthritis 時(shí)間: 2025-3-30 18:26
Low Molecular Weight Heparin,n and treatment of venous thromboembolism. The low molecular weight heparins have also been used in clinical trials for the prevention and treatment of arterial thrombosis. In this chapter, we review the problems related to the use of unfractioned heparin, compare the low molecular weight heparins w作者: Palpate 時(shí)間: 2025-3-30 21:10
Inhibitors of Factor Xa,o activate factors V, VIII and XI. Recruitment of these additional factors begins the “augmentation stage” which can provide large amounts of additional thrombin that plays a dominant role in subsequent thrombus formation. In both the classical coagulation cascade and the more current tissue factor 作者: 發(fā)炎 時(shí)間: 2025-3-31 02:22
Inhibitors of Tissue Factor/Factor VIIa, of additional thrombin and, thereby, fibrin. Although the TF/VIIa complex is not directly responsible for the production of all of the thrombin needed to form a complete thrombus, it plays the crucial role of initiating the process.作者: 我不怕犧牲 時(shí)間: 2025-3-31 08:55
Natural Anticoagulants and Their Pathways, exposure of negatively charged phospholipids. These clotting reactions are offset by natural anticoagulant mechanisms, the most important of which are thought to include the tissue factor pathway inhibitor (Chap. 15), antithrombin-heparin (Chap. 9) and the protein C anticoagulant pathway (depicted 作者: nostrum 時(shí)間: 2025-3-31 10:27 作者: 惡臭 時(shí)間: 2025-3-31 16:02
